Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 21, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Steve Valiquette Maintained (TDOC) at Buy with Decreased Target to $25 on, Feb 21st, 2024
Steve Valiquette of Barclays, Maintained "Teladoc Health, Inc." (TDOC) at Buy with Decreased Target from $26 to $25 on, Feb 21st, 2024.
Steve has made no other calls on TDOC in the last 4 months.
There are 2 other peers that have a rating on TDOC. Out of the 2 peers that are also analyzing TDOC, 1 agrees with Steve's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Lisa Gill of "JP Morgan" Maintained at Hold with Decreased Target to $19 on, Friday, November 17th, 2023
This is the rating of the analyst that currently disagrees with Steve
- Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $26 on, Wednesday, October 25th, 2023
